Preclinical Profile of Zoledronic Acid in Prostate Cancer Models Jonathan R. Green  European Urology Supplements  Volume 3, Issue 5, Pages 16-24 (November 2004) DOI: 10.1016/j.eursup.2004.08.008 Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 1 Effects of zoledronic acid and pamidronate on viability of human prostate cancer cell lines. *Indicates statistically significant reductions from baseline (p < 0.001). Adapted with permission from Oades et al. [53]. European Urology Supplements 2004 3, 16-24DOI: (10.1016/j.eursup.2004.08.008) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 2 Synergistic effect of zoledronic acid plus paclitaxel on apoptosis of MCF-7 breast cancer cells in vitro. Data from Jagdev et al. [55] and reproduced with permission from Clézardin [57]. European Urology Supplements 2004 3, 16-24DOI: (10.1016/j.eursup.2004.08.008) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 3 Radiographic imaging of mouse tibiae bearing osteolytic PC-3 or osteoblastic LuCaP 23.1 tumors from control animals and animals treated with zoledronic acid (5μg SC twice weekly). Zoledronic acid was administered either at the time of tumor cell injection (prevention) or after tumors were established (treatment). Adapted with permission from Corey et al. [11]. European Urology Supplements 2004 3, 16-24DOI: (10.1016/j.eursup.2004.08.008) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 4 Bone histomorphometric analysis to tibiae injected with either (A) PC-3 or (B) LuCaP 23.1 human prostate cancer cells from animals treated with vehicle or zoledronic acid either at the time of tumor cell injection (prevention) or after bone tumors were established (treatment). Data are presented as percent tumor volume versus total tissue volume. *p < 0.03. †p < 0.001. Adapted with permission from Corey et al. [11]. European Urology Supplements 2004 3, 16-24DOI: (10.1016/j.eursup.2004.08.008) Copyright © 2004 Elsevier B.V. Terms and Conditions

Fig. 5 Blood concentration of prostate-specific antigen (PSA) over time in animals bearing LuCaP 23.1 tibial tumors and treated with zoledronic acid either at the time of tumor cell injection (prevention) or after bone tumors were established (treatment). Data expressed as mean ± standard error of the mean at each time point. Adapted with permission from Corey et al. [11]. European Urology Supplements 2004 3, 16-24DOI: (10.1016/j.eursup.2004.08.008) Copyright © 2004 Elsevier B.V. Terms and Conditions